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Abstract
Background: Aurora B kinase is an important mitotic kinase involved in chromosome segregation and cytokinesis.
It is overexpressed in many cancers and thus may be an important molecular target for chemotherapy. AZD1152 is
the prodrug for AZD1152-HQPA, which is a selective inhibitor of Aurora B kinase activity. Preclinical antineoplastic
activity of AZD1152 against acute myelogenous leukemia, multiple myeloma and colorectal cancer has been
reported. However, this compound has not been evaluated in breast cancer, the second leading cause of cancer
deaths among women.
Results: The antineoplastic activity of AZD1152-HQPA in six human breast cancer cell lines, three of which
overexpress HER2, is demonstrated. AZD1152-HQPA specifically inhibited Aurora B kinase activity in breast cancer
cells, thereby causing mitotic catastrophe, polyploidy and apoptosis, which in turn led to apoptotic death.
AZD1152 administration efficiently suppressed the tumor growth in a breast cancer cell xenograft model. In
addition, AZD1152 also inhibited pulmonary metastatic nodule formation in a metastatic breast cancer model.
Notably, it was also found that the protein level of Aurora B kinase declined after inhibition of Aurora B kinase
activity by AZD1152-HQPA in a time- and dose-dependent manner. Investigation of the underlying mechanism
suggested that AZD1152-HQPA accelerated protein turnover of Aurora B via enhancing its ubiquitination.
Conclusions: It was shown that AZD1152 is an effective antineoplastic agent for breast cancer, and our results
define a novel mechanism for posttranscriptional regulation of Aurora B after AZD1152 treatment and provide
insight into dosing regimen design for this kinase inhibitor in metastatic breast cancer treatment.
Background
Aurora kinases are a family of serine/threonine kinases
which share ~70% homology in their kinase domains
[1-3], and they are essential in cell cycle control and
mitosis [3-6]. Mammalian cells have three Aurora family
members: A, B and C. The Aurora kinases are expressed
at maximum levels during mitosis. Aurora A and B have
different subcellular localizations and serve distinct
functions during mitosis. Together, they tightly manage
chromosome segregation to ensure that each resulting
daughter cell receives a full complement of chromo-
somes [3-5]. All three Aurora kinases have been shown
to be amplified or overexpressed in human cancer and
contribute to tumorigenesis through their link to inva-
sive disease and genomic instability [3]. By virtue of
their important role in cell proliferation and their onco-
genic potential [7], the Aurora kinases are potentially
important targets for cancer therapeutics.
In contrast to Aurora A which localizes to the centro-
somes and contributes to spindle bi-polarity by mana-
ging microtubule assembly and centrosome
organization, Aurora B maintains correct kinetochore-
microtubule attachments and is localized to the chro-
mosomes during metaphase. Aurora B relocalizes to the
midbody of the cell during late anaphase and telophase,
which hints at an additional function during cytokinesis
[4]. Aurora B phosphorylates Histone H3 at serine 10
leading to dissociation of Histone H1 and chromatin
condensation [8]. As a regulator of chromosome segre-
gation, Aurora B is part of the Chromosome Passenger
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Borealin and Survivin. The CPC governs the spindle
checkpoint and manages correct microtubule attach-
ments to kinetochores [6-9].
Aurora B has been demonstrated to be overexpressed in
multiple myeloma [10], AML [1], colorectal [7], prostate
[11] and pancreatic [12] cancers. In human breast cancer,
an oncogenic link to Aurora B has not been made
although Aurora A may be overexpressed in 95% of cases
[13] and may be used as a predictor of survival [14]. Over-
expression of Aurora A may not simply be a gain of onco-
genic function, rather Aurora A may be interfering with
the delicate balance of Aurora B in the cell [15]. Aurora A
kinase activating mutationsd on o tf u r t h e re n h a n c et h e
transformation phenotype of Aurora A [16]. Inhibition
kinase activities of both Aurora A and B by ZM447439, a
pan Aurora kinase inhibitor, results in cellular changes
that most resemble loss of Aurora B function [15], and
mutations in Aurora B confer resistance of HCT116 cells
to ZM447439 [17]. Therefore, Aurora B may in fact be a
more important drug target than Aurora A.
In this study, the knowledge gap regarding the use of
the Aurora B-specific inhibitor, AZD1152, in breast can-
cer is addressed. AZD1152 is a dihydrogen phosphate
prodrug and is metabolized in the serum to its active
form, AZD1152-HQPA [hydroxyquinazoline pyrazol ani-
lide], which is a small molecule ATP binding pocket
competitor [18]. AZD1152-HQPA has potent selectivity
for inhibition of Aurora B [Ki = 0.36 nM] compared
with Aurora A [Ki = 1,369 nM] and a panel of 50 other
kinases [7]. The antineoplastic effect of this drug has
been demonstrated in human cancer cell lines, including
colon, lung, and cervix [7], as well as leukemia cell lines
and primary acute myeloid leukemia cultures [1].
Also evaluated were the dose-responses of AZD1152-
HQPA in 6 human breast cancer cell lines as well as the
cellular consequences of Aurora B inhibition. Further,
the antineoplastic effects of AZD1152 in nude xenograft
mice using two breast cancer cell lines were examined.
This was followed by the novel discovery that this Aur-
ora B kinase inhibitor downregulated Aurora B protein
level by increasing polyubiquitination and proteasomal
degradation of Aurora B. Together, these studies indi-
cate that AZD1152 has antineoplastic activity in human
breast cancer cells and that AZD1152’s impact on Aur-
ora B protein stability is another important layer of reg-
ulation that has not been characterized before.
Results
Breast cancer cells are sensitive to AZD1152-HQPA in
vitro and display signs of mitotic catastrophe after
exposure
To evaluate the effect of AZD1152-HQPA on breast can-
c e rc e l l s ,H E R 1 8( E R + ,P R + ,p 5 3 w t )b r e a s tc a n c e rc e l l s ,
which stably overexpress HER2 (parent line, MCF-7)
[19], were treated with AZD1152-HQPA. Cell prolifera-
tion was measured by MTT assay (Figure 1). The concen-
tration that achieves 50% of maximal inhibition of
proliferation (IC50) of the cells was measured at 20 nM
by sigmoidal curve fitting. Similar results were obtained
in MDA-MB-468 (HER2+, EGFR+++, Pten-, ER-, PR-,
p53 mutant), MDA-MB-435 (HER2+[16], ER-, PR-, p53
mutant), MDA-MB-231 (HER2+[16], ER-, PR-, p53
mutant), MDA-MB-361 (HER2+++, ER+, PR+, p53wt)
and BT-474 (HER2+++[14], ER+, PR+, p53 mutant) at
IC50 of 14 nM, 125 nM, 105 nM, 70 nM and 8 nM
respectively. All human breast cancer cell lines tested
showed sensitivity to AZD1152-HQPA with typical sig-
moidal log (dose)-response curves. The observed IC50s
a r ec o m p a r a b l et ot h o s ef o u n di nl e u k e m i aa n do t h e r
human cancer cell lines [1,7]. To verify the response to
drug inhibition by MTT assay, a separate dose-response
assay in HER18 cells measuring proliferation inhibition
by live cell count, which corroborated the IC50 of 20 nM
for HER18 cells (data not shown), was performed. These
results suggest that AZD1152-HQPA is an effective inhi-
bitor of human breast cancer cells by MTT assay, a mea-
sure of both cell proliferation and cell death. Further, this
effect was seen in various cell lines with multiple molecu-
lar profiles for HER2, ER, PR and p53.
Treatment with AZD1152 causes mitotic catastrophe,
G2/M arrest and polyploidy/aneuploidy
Given the important role of Aurora B kinase in mitosis,
the impact of AZD1152-HQPA on chromosome segre-
gation was investigated. HER18 cells were incubated
with or without 20 nM AZD1152-HQPA for 48 hours.
Chromosomal DNA was stained with DAPI and mitotic
cells were observed by fluorescence microscopy. While
control HER18 cells showed normal morphology (Figure
2A), cells treated with AZD1152-HQPA demonstrated
characteristics of mitotic catastrophe including multi-
nucleation, micronuclei and chromosome bridges
(arrows and arrow heads). Quantification of this effect
was performed and it was found that approximately 60%
of drug-treated cells exhibited signs of mitotic cata-
strophe versus 3% for control cells (Figure 2B). These
observations are consistent with the effects of loss of
Aurora B function and demonstrate that AZD1152-
HQPA is effective in causing mitotic catastrophe in
breast cancer cells.
Measurement of the DNA content of individual
HER18 cells treated with AZD1152-HQPA using flow
cytometry after propidium iodide (PI) staining of DNA
revealed that the percentage of 4N HER18 cells
increased after treatment with AZD1152-HQPA 20 nM
(Figure 2C). Importantly, HER18 cells with DNA con-
tent greater than 4N began to appear after 48 hours of
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Page 2 of 13exposure to AZD1152-HQPA. The percentages of 2N,
4N and 8N cells were quantified from the flow cytome-
try data and are displayed in Figure 2D. It can be seen
that as G2/M (4N) cell percentages increase, there is a
concomitant decrease in G1 (2N) cell percentages. Poly-
ploid (8N) cells increased from 1.35% of the cell popula-
tion at 24 hours to 9.7% at 48 hours. In Figure 2E,
polyploid cell numbers were analyzed relative to the
number of 8N cells at time 0. By 48 hours, the number
of 8N cells had increased 12.8 fold. This evidence,
together with the observation of nuclear morphologic
changes reported above, indicates that cells become
polyploid or aneuploid as mitotic catastrophe occurs
after treatment with AZD1152-HQPA.
AZD1152-HQPA causes apoptosis and decreases
clonogenic potential in breast cancer cells
Next, AZD1152-HQPA treatment as the cause of cell
death via apoptosis was investigated. HER18 cells were
treated with AZD1152-HQPA (100 nM) for up to 48
hours, followed by staining with Annexin V-FITC/PI
and analysis by flow cytometry (Figure 3A, upper
panels). Percentages of cells in both early (lower right
panel) and late (upper right panel) apoptosis increased
with increasing duration of exposure to AZD1152-
HQPA. After 24 hours of treatment, there were 9.22%
apoptotic cells and 15.57% at 48 hours, compared to
5.64% in the untreated control cells (Figure 3A). Similar
results were obtained with the parent cell line MCF7
(data not shown) as well as MDA-MB-231 (Figure 3A,
lower panels). Apoptosis following AZD1152-HQPA
treatment was also examined by immunoblotting to
detect specific PARP (Poly [ADP-Ribose] Polymerase)
cleavage by Caspase-3 in HER18 and MDA-MB-231
cells (Figure 3B). Increases in cleaved PARP in both cell
types treated with AZD1152-HQPA were observed. This
corresponds with the IC50 for these cell lines (Figure 1)
and these results confirm that treatment with
AZD1152-HQPA leads to apoptosis.
To determine if AZD1152-HQPA can inhibit the
colony forming potential of breast cancer cells,
HER18 cells were incubated at a low density with
either control culture medium or 40 nM AZD1152-
HQPA. After 12 days, colonies were stained with
crystal violet and counted (Figure 3C). AZD1152-
HQPA inhibited the ability of HER18 cells to form
colonies (Figure 3C and 3D). The difference in the
mean colony numbers per cm
2 between the control
and AZD1152-HQPA groups was significant (P <
0.001, two-sided Student’s t-test). Next, the ability of
Figure 1 AZD1152-HQPA inhibits breast cancer cell proliferation. Live cells were measured by MTT assay. Log(dose)-response curves for
HER18, MDA-MB-468, MDA-MB-435, MDA-MB-231, MDA-MB-361 and BT474 are shown as labeled. Each data point represents the mean of at
least 4 replicates; error bars represent 95% confidence intervals. Each IC50 was calculated based on sigmoidal curve fitting to the respective data
set.
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growth of breast cancer cells was examined by using
the soft agar colony forming assay. The mean colony
number in soft agar was also significantly (P < 0.001,
two-sided Student’s t-test) decreased by 80 nM
AZD1152-HQPA compared with the control in both
(Figure 3E).
Taken together, these results indicate that AZD1152-
HQPA has the ability to inhibit breast cancer cells by
inducing apoptosis and decreasing their colony forming
potential in both anchorage dependent and independent
environments.
Aurora B inhibition by AZD1152 inhibits tumor growth in
an orthotopic xenograft nude mouse model
To evaluate the in vivo effect of AZD1152 against
aggressive breast cancer, HER18 human breast cancer
cells were xenografted orthotopically into nude mice. 8.5
×1 0
6 HER18 cells were injected into the mammary fat
pad of each female athymic nu/nu mice that received
weekly subcutaneous estradiol cypionate injections
(3 mg/kg/dose) [20,21] starting 2 weeks prior to injec-
tion of tumor cells. When tumors were measurable
(approximately 50 mm
3, see Figure 4A), the mice were
randomized into 3 groups: control (n = 6) which
Figure 2 AZD1152-HQPA causes mitotic defects, aneuploidy and polyploidy in breast cancer cells.( A )H E R 1 8c e l l sw e r et r e a t e dw i t h
control culture medium or 20 nM AZD1152-HQPA for 48 hours, stained with DAPI and examined using fluorescence microscopy. Interphase cells
showed bi-nucleation (arrow) and micronuclei (arrow heads). Metaphase cells showed misaligned chromosomes (arrow). Anaphase cells showed
misegregated chromosomes (arrow) and chromosomal bridges (arrow head). (B) Percentage of cells from A with mitotic catastrophe is plotted
for vehicle and 20 nM AZD1152-HQPA treatments. (C) HER18 cells were treated with AZD1152-HQPA (100 nM) for indicated times and stained
with propidium iodide prior to analysis of DNA content by flow cytometry. Gating indicates 2N (G1), 4N (G2/M) and 8N (polyploid) cells.
Aneuploid cells were present between 4N and 8N after 48 h treatment. (D) Percentages of 2N, 4N and 8N cells are plotted at 0, 24 and 48 hour
time points based on the data in C. (E) Number of 8N cells relative to 0 hours.
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Page 4 of 13Figure 3 AZD1152-HQPA induces apoptosis and reduces clonogenic potential in breast cancer cells. (A) HER18 and MDA-MB-231 cells
were exposed to AZD1152-HQPA (100 nM and 105 nM) for up to 72 hours and cells were stained with Annexin V-FITC plus propidium iodide.
Samples were analyzed by flow cytometry for PI (y-axis) and Annexin V (x-axis) at 3 time points. Representative scattergrams are shown with
percentages of cells displayed for each quadrant: Lower Left - live cells, Lower Right - early apoptosis, Upper Right - late apoptosis and Upper
Left - necrotic cells. Overall percent apoptosis was calculated for each time point by adding Lower Right and Upper Right quadrants. (B)
Apoptosis of HER18 and MDA-MB-231 cells was analyzed by Western blotting with anti-PARP antibody. PARP appears at 115 KD while the
apoptotic indicator, cleaved PARP, appears at 85 KD. (C) HER18 cells were plated in triplicate at 5000 cells/plate in 6 cm tissue culture dishes and
treated with either vehicle or 40 nM AZD1152-HQPA. Representative plates are shown after incubation for 12 days and staining with crystal
violet. (D) Mean colony numbers from C are plotted for AZD1152-HQPA versus control. (E) Soft agar clonogenic assay was performed using
HER18 cells. Mean soft agar colony numbers from triplicate plates are plotted for AZD1152-HQPA versus control. All Error bars represent 95%
confidence intervals.
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Page 5 of 13received 200 μl of 0.3 M Tris pH 9.0, low dose (n = 8)
which received 62.5 mg/kg/dose AZD1152, and high
dose (n = 6) which received 125 mg/kg/dose AZD1152.
Doses of AZD1152 were based on the pharmacokinetic
findings of previous publications that a dose of 10-150
mg/kg/day produced sufficient plasma concentrations of
AZD1152 in nude mice [7,18]. Injections were adminis-
tered IP on days 1 and 2 of a 7-day repeating cycle for 3
cycles. The mice treated with high dose AZD1152
showed reduced tumor volume compared to control
mice (P < 0.001) and low dose treated mice showed a
near-significant reduction (P < 0.08) (Figure 4A and 4B).
Excised tumors in the drug-treated groups weighed sig-
nificantly (P < 0.01, one-wayA N O V A ,p o s t - h o ci n t e r -
group comparison using Tukey test) less than those in
the control mice (Figure 4C).
Formalin-fixed tumor samples were embedded in par-
affin, and sections were examined by microscopy. Con-
sistent with the in vitro data from Figure 2,
multinucleate cells were observed on the hematoxylin-
and eosin-stained (H&E) histological slides of tumor
samples from AZD1152-treated mice but not on the
slides of tumors from control mice (Figure 4D). Tumor
samples were also snap-frozen in liquid nitrogen, and
proteins were subsequently extracted for immunoblot-
ting. Aurora B is known to phosphorylate serine 10 of
Histone H3 [22] to aid in chromatin condensation by
dissociating Histone H1 from heterochromatin [23,24].
Therefore, inhibition of Aurora B kinase activity can be
verified by immunoblotting with phospho-specific anti-
body to serine 10 of Histone H3 [8]. A reduction in
phospho-Histone H3 in AZD1152-treated tumors com-
pared with control tumors (Figure 4E) was found, con-
firming that AZD1152 inhibited Aurora B kinase activity
in vivo (i.e., confirming the pharmacodynamic mechan-
ism). Immunohistochemistry staining for Ki-67 (a cell
proliferation marker) and cleaved Caspase 3 (a marker
of apoptosis) revealed that Ki-67 was markedly reduced
in both drug treated groups when compared with the
control group and that Caspase 3 cleavage was increased
in the drug-treated groups versus the control. This pro-
vides evidence that AZD1152 induced apoptosis in
breast cancer cells and inhibited breast cancer cell pro-
liferation in vivo (Figure 4F).
AZD1152 inhibits breast cancer metastasis
In the above orthotopic xenograft assay spontaneous
metastasis of tumors in either control or treatment
groups was not observed. To address the question of
whether AZD1152 could block metastases of breast can-
cer as well as growth of primary tumors, a breast cancer
xenograft model with lung metastasis potential was
employed. MDA-MB-231 human breast cancer cells
k n o w nt ob eh i g h l ym e t a s t a t i cw e r eu s e di nt h i s
experimental assay. Six to eight week old female athymic
nu/nu mice were injected via tail vein with 2 × 10
6
MDA-MB-231 human breast cancer cells. Mice were
randomized into 2 groups: control and AZD1152. Treat-
ment with vehicle or AZD1152 (125 mg/kg/dose) began
2 days after intravenous injection of breast cancer cells.
Drug or vehicle were administered IP on days 1 and 2
of a 7-day repeating cycle for 4 weeks only. Ten weeks
after injection of cancer cells, mice were sacrificed, and
the lungs were removed and weighed. The mean weight
of lung tissue per mouse in the control group was sig-
nificantly (P < 0.01, two-tailed t-test) higher than that in
the AZD1152 group (Figure 5A). Further, the number of
macroscopic tumor nodules was found to be signifi-
cantly (P < 0.008, two-tailed t-test) higher in the lungs
of control mice compared with AZD1152-treated mice
(Figure 5C). Gross anatomic appearance of matched
lung lobes from representative mice is shown in Figure
5B. H&E staining of lung tissues from control and
AZD1152-treated mice showed reduction of tumor bur-
den by AZD1152 at the microscopic level (Figure 5D).
The data show that AZD1152 is effective in inhibiting
the aggressive and highly metastatic phenotype of
MDA-MB-231 human breast cancer cells in vivo.
AZD1152 reduces Aurora B protein level by increasing
polyubiquitination and degradation via the proteasome
Examination of the impact of AZD1152-HQPA on Aur-
ora B by immunoblotting also revealed that AZD1152-
HQPA inhibits Aurora B kinase activity. This was
reflected by a decrease in both phosphorylated Histone
H3, and Aurora B protein level in a dose- and time-
dependent manner (Figure 6A). The time courses
showed that inhibition of Aurora B kinase activity pre-
ceded the decline in Aurora B protein level (Figure 6A).
The unexpected finding of a decrease in Aurora B pro-
tein level was further investigated by examining the
impact of AZD1152-HQPA on the protein turnover rate
of Aurora B. HER18 cells were treated with or without
20 nM AZD1152-HQPA for 48 hours, then in the pre-
sence of cycloheximide (CHX) for up to four additional
hours. After immunoblotting to measure Aurora B pro-
tein level (Figure 6B), the Aurora B protein band was
quantified by densitometry. Relative protein level was
calculated as the ratio of the integrated optical density
of the Aurora B relative to time 0. The Aurora B protein
turnover rates were determined as the slope of the lin-
ear regression line through each set of data points
(Figure 6C). As indicated by the slope, AZD1152-HQPA
increased the turnover rate of Aurora B. To test if the
turnover of Aurora B was via the proteasome pathway,
an experiment in which MDA-MB-231 cells were trea-
ted with or without AZD1152-HQPA in the presence of
the proteasome inhibitor, MG132 (Figure 6D) was
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Page 6 of 13Figure 4 AZD1152 inhibits orthotopically xenografted HER18 cells in nude mice. (A) Tumor growth curves for orthotopically implanted
HER18 cells are shown. Control mice received vehicle (0.3 M Tris pH 9.0), low dose mice received 62.5 mg/kg/dose AZD1152, and high dose
mice received 125 mg/kg/dose AZD1152. Treatment began when tumors were measurable (approximately 50 mm
3). Injections were given IP on
days 1 and 2 of 7-day cycles, indicated by horizontal bars just above the x-axis. * P < 0.001 calculated as a mixed linear model. Error bars
represent SE. (B) Representative mice bearing xenografts (arrows) from each treatment group. (C) Weights of dissected xenografts are plotted as
means for each treatment group. Error bars represent 95% confidence intervals. P values were determined by one-way ANOVA. (D) H&E stained
control and high dose (125 mg/kg/day) tumor samples are shown. Multi-nucleate cells (circles) were observed in tumor sections from AZD1152-
treated mice but not in control mice. (E) Western blots using anti-phospho-Histone H3 and anti-actin are shown as labeled. (F) Histology and
immunohistochemistry of xenografts are shown: top panels- H&E staining; middle panels- immunohistochemistry with antibodies for Ki-67; lower
panels- cleaved Caspase 3.
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Page 7 of 13Figure 5 AZD1152 inhibits growth of lung tumor nodules in a lung metastasis nude mouse model. (A) Two million MDA-MB-231 human
breast cancer cells were injected via tail veins of nude mice. AZD1152 (125 mg/kg/dose) or vehicle were administered IP on days 1 and 2 of 7-
day repeating cycle for 4 cycles starting 2 days after cancer cell injection. Ten weeks after cancer cell injection, the mice were sacrificed and
lungs were weighed and plotted as the means for each treatment group. (B) Matched lobes of the lungs from a representative mouse from
each group are shown as labeled. (C) The number of macroscopic tumor nodules in the lungs was counted in each mouse. The mean number
of nodules per mouse was plotted for each group. Error bars represent 95% confidence intervals. (D) H&E stained slides of lungs from control
and drug treated mice are shown at the same magnification. Arrows indicate metastatic lung tumors.
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Page 8 of 13Figure 6 AZD1152 reduces Aurora B protein level by increasing poly-ubiquitination and degradation via the proteasome. (A) Western
blots were performed for Aurora B, phospho-Histone H3 and actin levels. HER18 cells were treated with increasing duration of AZD1152 20 nM
(left panel) and with increasing concentration of AZD1152 for 48 hours (right panel) as labeled. (B) HER18 cells were treated with or without 20
nM AZD1152 for 48 hours and then in the presence of cycloheximide for up to four hours. Immunoblots of Aurora B and actin are shown. (C)
The integrated optical densities of the protein bands in B. The amount of Aurora B protein relative to 0 h of cycloheximide treatment was
calculated for each group and corrected for gel loading differences based on actin. The relative rates of Aurora B turnover were estimated by
the slope of the linear regression line for the control and AZD1152-HQPA-treated cells. (D) MDA-MB-231 cells show increased Aurora B protein
levels when treated with the proteasome inhibitor MG132 and AZD1152-HQPA versus AZD1152-HQPA treatment alone. (E) AZD1152-HQPA
causes increased poly-ubiquitinated Aurora B versus control. HER18 cells were transfected with the plasmids (Flag-Aurora B and HA-ubiquitin)
and treated with the drugs (AZD1152-HQPA and the proteasome inhibitor MG132) as labeled above the top panel. Top panel: anti-HA
immunoblot of anti-Flag-immunoprecipitates. Bottom panels: Anti-Flag immunoblot of whole cell lysates. (F) AZD1152-HQPA may disturb mitosis
in at least two pathways: 1) through inhibition of Aurora B kinase activity, and 2) through increasing poly-ubiquitination and proteasomal
degradation of Aurora B protein leading to decreased Aurora B function.
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levels were rescued by inhibition of the proteasome in
the presence of AZD1152-HQPA.
Next, the ubiquitination of Aurora B in the presence
of AZD1152-HQPA was investigated. HER18 cells were
transfected with Flag-tagg e dA u r o r aBa n dH A - t a g g e d
ubiquitin. The transfected cells were incubated in the
presence or absence of 20 nM AZD1152-HQPA. All
samples were incubated with MG132 (10 μg/ml, 5 h) to
inhibit the proteasome. Immunoprecipitation with anti-
Flag antibody followed by immunoblotting with anti-HA
antibody demonstrated the presence of polyubiquiti-
nated Aurora B in cells transfected with both plasmids
while no polyubiquitinated Aurora B and only the IgG
heavy chain band was detected in cells transfected with
Flag-Aurora B only (Figure 6E). Taken together, these
results suggest that subsequent to inhibition of Aurora
B kinase activity by AZD1152-HQPA, Aurora B protein
turnover was increased by polyubiquitination and pro-
teasomal degradation.
Discussion
In this study, a knowledge gap regarding the use of an
Aurora B kinase inhibitor in models of breast cancer
was addressed. AZD1152-HQPA has the ability to inhi-
bit a range of human breast cancer cell lines with IC50s
in the range of 8-125 nM (Figure 1), which is similar to
the range for leukemia [1] and colorectal cancer [7] cell
lines. This concentration range is well below the con-
centrations where AZD1152-HQPA would inhibit Aur-
ora A or other kinases [1]. Further, these six cell lines
have various molecular profiles for HER2, ER, PR and
p53. This is a potentially important finding in that this
drug may provide an alternative method for treatment
of breast cancer regardless of its molecular profile. One
of the breast cancer cells lines assayed, MB-MDA 231
(HER2+ [16], ER-, PR-, p53 mutant), is considered to be
a “triple negative” form of breast cancer. AZD1152-
HQPA was also shown to be effective in this line which
underscores the potential therapeutic value of this drug
in a limited druggable-target form of breast cancer.
While investigating the cellular effects of AZD1152-
HQPA it was found that it caused mitotic catastrophe
resulting in aneuploidy, polyploidy and various other
chromosomal abnormalities (Figure 2). Treatment with
AZD1152-HQPA in breast cancer cells also led to apop-
tosis (Figure 3) as previously found in leukemia, multi-
ple myeloma and colorectal cancer cells [1,7,10].
Additionally, it was found that colony forming potential
in both anchorage dependent and anchorage-indepen-
dent assays were reduced by this drug. These cell cul-
ture data prompted further investigation into the
antineoplastic activity of AZD1152 in an in vivo model.
In an orthotopic xenograft model (Figure 4) and a
lung metastasis model (Figure 5) of breast cancer, the
in vivo antineoplastic effect of AZD1152 is demon-
strated. The pharmacodynamic mechanism of inhibition
of Aurora B kinase activity is confirmed in vivo by the
decrease in phosphorylation of Histone H3 at serine 10
in xenografts as measured by immunoblotting with
phospho-specific antibody. AZD1152 was well tolerated
by the mice and no digestive distress or significant
weight loss was observed. The in vivo antineoplastic
effect demonstrated in these experiments warrants
further investigation of this drug in clinical trials for
breast cancer.
It has been discovered that in addition to inhibiting
Aurora B kinase activity, AZD1152-HQPA also
decreases Aurora B protein level in a dose- and time-
dependent manner (Figure 6A). Mechanistic studies
show that AZD1152-HQPA increases the turnover rate
of Aurora B by increasing polyubiquitination and pro-
teasomal degradation. The results uncover a previously
unknown regulatory circuitry of AZD1152. Until now,
no Aurora kinase inhibitor has been reported to affect
the protein level of any Aurora kinase. These results
also generate new hypotheses. Because Aurora B is
autophosphorylated [25], it remains to be determined
whether AZD1152 can cause inhibition of autopho-
sphorylation, thereby enhancing the Aurora B degrada-
tion. Such a possibility will be another interesting layer
of regulation to explore. These findings highlight the
complexity of AZD1152’s impact on post-translational
regulation of Aurora B and provide the important
insight that the inhibitory effect of AZD1152-HQPA
may persist after wash-out of the drug from the target
tissue. Theoretically, the inhibition of Aurora B should
persist until the Aurora B protein level returns to nor-
mal. Therefore, the biological effects could be expected
to last longer than the presence of the active inhibitor
AZD1152-HQPA. This novel finding may aid the proper
interpretation and use of pharmacokinetic and pharma-
codynamic information about this drug to improve
design of clinical dosing regimens.
Conclusions
AZD1152-HQPA has antineoplastic activity against
breast cancer cells in culture, and AZD1152 suppressed
breast cancer growth in two mouse models. AZD1152-
HQPA accelerated turnover of Aurora B protein by
increasing poly-ubiquitination and proteasomal degrada-
tion. The finding that AZD1152-HQPA downregulates
Aurora B protein level as well as inhibits Aurora B
kinase activity (Figure 6F) will be important for the
interpretation of pharmacokinetics and pharmacody-
namics of AZD1152.
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Cell lines
HER18 cells (stably expressing HER2) were described
previously [19] and were cultured in DME/F12 media
(Sigma, St. Louis, MO) supplemented with 10% (v/v)
fetal bovine serum (Gemini, West Sacramento, CA).
Human breast cancer cell lines MDA-MB-231, MDA-
MB-435, MDA-MB-361, BT-474 and MDA-MB-468
were obtained from ATCC (Manassas, VA, USA).
MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells
were cultured in Leibovitz’s L15 media (Cellgro, Mana-
ssas, VA) with 10% (v/v) fetal bovine serum, 2 mM L-
glutamine (Cellgro, Manassas, VA) and 1% (v/v) antibio-
tic-antimycotic solution (Invitrogen, Grand Island, NY).
BT-474 and MDA-MB-361 were cultured in DME/F12
media (Sigma, St. Louis, MO) supplemented with 10%
(v/v) fetal bovine serum (Gemini, West Sacramento,
CA). All the cells were incubated at 37°C with 5% CO2.
Compounds and antibodies
Antibodies used in Western blots include: anti-phospho-
Histone H3 (p-HH3) (Upstate, Lake Placid, NY), anti-
PARP (Cell Signaling, Danvers, MA), anti-Aurora B
(Abcam, Cambridge, MA), anti-HA (Sigma) and anti-
actin (Sigma). The protein synthesis inhibitor cyclohexi-
mide and proteasome inhibitor MG132 were purchased
from Sigma Chemical Co. (St. Louis, MO).
AZD1152 prodrug and its metabolite, AZD1152-
HQPA, were provided by Astra Zeneca Pharmaceuticals
(Macclesfield, Cheshire, UK). AZD1152-HQPA was dis-
solved in 100% DMSO at 10 mM, and used at indicated
durations and concentrations after dilution in tissue cul-
ture media. AZD1152 was dissolved in 0.3 M Tris pH
9.0 (Fisher, Pittsburgh, PA) and 0.2% DMSO (Fisher) at
a maximum concentration of 20 mg/ml. The AZD1152
solution was made fresh for each round of injection into
mice.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay
Cell lines were seeded at 5-20% confluence in 96-well
microplates and allowed to attach for 24 hours.
AZD1152-HQPA was serially diluted in appropriate
complete media to the stated final concentrations. Plates
were incubated for 2 to 5 days. Following incubation, 20
μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) (Sigma) was added to each well.
After incubation for 1 to 5 hours, the media were
replaced by 200 μl 100% DMSO in each well. After mix-
ing, the microplates were read with an MRX revolution
plate spectrophotometer (Dynex, Technologies, Chan-
tilly, VA) at 570 nm. Averages of at least 4 replicates
were plotted and 50% inhibitory concentrations (IC50)
were estimated based on sigmoidal curve fitting. For
validation of MTT method in HER18 cells, cells from 6-
cm-diameter dishes after similar treatment with
AZD1152-HQPA were counted using a Z1 Coulter par-
ticle counter (Beckman Coulter, Fullerton, CA), and
average counts from triplicate plates were plotted
against concentration of AZD1152-HQPA.
Evaluation of in vivo antineoplastic activity
Six- to eight-week old female athymic (nu/nu) mice
(Experimental Radiation Oncology, MD Anderson Can-
cer Center, Houston, TX, USA) were housed in AAA-
LAC approved barrier facilities on a 12-hour light/dark
cycle, with food and water ad libitum. Mice were treated
under approved protocols in compliance with the animal
care and use guidelines of our institution, the USDA and
the NIH. For the breast cancer orthotopic xenograft
model, nude mice were injected with 8.5 × 10
6 HER18
human breast cancer cells in the mammary fat pad
[26,27]. The nude mice were supplemented with weekly
subcutaneous estradiol cypionate (Pfizer, NY, NY) injec-
tions (3 mg/kg/week) [20,21] starting 2 weeks prior to
injection of tumor cells. Mice were randomized into 3
groups and treatment with AZD1152 prodrug began
when tumors were measurable (approximately 50 mm
3).
Control mice received IP injections of vehicle (0.3 M Tris
pH 9.0), low dose group received 62.5 mg/kg/day of
AZD1152, and the high dose group received 125 mg/kg/
day of AZD1152 on days 1 and 2 of a 7-day cycle for 3
cycles. Tumor measurements were taken every 2 to 3
days, and volumes were estimated with this formula:
Length × Width
2/2 [28]. Mice were sacrificed 24 days
post tumor cell injection, and tumors were dissected.
Tumor samples were snap frozen for Western blotting or
fixed in formalin and paraffin embedded for histological
analysis. Immunohistochemistry (IHC) was performed
using the ABC kit (Vector Lab.) according to standard
techniques. Photomicrographs were taken at 200× mag-
nification with an Olympus IX70 microscope and Olym-
pus DP controller imaging software (version. 3.2.1.276).
For the breast cancer lung metastasis model, nude
mice were injected with 2 × 10
6 MDA-MB-231 cells via
a tail vein. Cells were suspended in 200 μlc o m p l e t e
media (DME/F12 with 10% fetal bovine serum). Mice
were randomized into 2 groups (control and AZD1152).
The AZD1152 group received injections of AZD1152
125 mg/kg/day IP on days 1 and 2 of a 7-day cycle for 4
cycles starting two days after tumor cell injection. Con-
trol mice received IP injections of vehicle (0.3 M Tris
pH 9.0). Mice were sacrificed 10 weeks after tumor cell
injection, and the lungs were weighed and examined for
tumor nodules. Tumor samples were fixed in formalin
and paraffin embedded for histological analysis.
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Breast cancer cells for cell cycle analysis were plated in
100-mm tissue culture dishes and allowed to attach for
24 hours. 100 nM AZD1152-HQPA or vehicle were
applied to each plate for indicated times and cells har-
vested by trypsinization (Ce l l g r o ,H e r n d o n ,V A ) .C e l l s
were collected and fixed in 70% ethanol for 1 hour fol-
lowed by additional washing in PBS pH 7.40. Propidium
iodide (PI) solution (50 μg/ml) with RNAseA (20 μg/ml)
(Qiagen, Valencia, CA) was added to each sample and
samples analyzed with a FACScalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Cells ana-
lyzed for apoptosis were plated in 100-mm dishes and
allowed to attach for 24 hours before addition of
AZD1152-HQPA. Cells were washed with PBS and tryp-
sinized at appropriate times for harvest. Cells were sus-
pended in 0.5 ml binding buffer (Axxora, San Diego,
CA) and 5 μlA n n e x i nV - F I T C( B D ,S a nJ o s e ,C A )f o r
15 minutes at room temperature in the dark. The cells
were washed again, and PI solution with RNAseA was
applied just before analysis.
Colony forming assays
Soft agar colony forming assays were performed in tri-
plicate plates with a base agar of 1× DME/F12 complete
medium with 0.5% low melt agar (Fisher) and either
DMSO for the control or 80 nM AZD1152-HQPA. Base
agar was added to 6 cm Petri dishes and allowed to set.
5000 cells/plate added to 0.35% top agar with control
medium or 80 nM AZD1152-HQPA. The plates were
incubated at 37°C with 5% CO2 for 26 days. Colonies
>100 cells were counted using a dissecting microscope,
and results were analyzed using the Student’s t-test.
Colony forming assays were performed in triplicate by
trypsinizing breast cancer cells and plating them in 6-
cm tissue culture dishes at 5000 cells/plate in complete
DME/F12 medium with either DMSO or 40 nM
AZD1152-HQPA. The plates were incubated for 12 days
at 37°C with 5% CO2 for 12 days. Colonies were
counted in 3 representative one cm
2 areas/plate and the
number colonies per cm
2 between AZD1152-HQPA-
treated cells and control cells were compared using Stu-
dent’s t-test.
Fluorescence microscopy
Breast cancer cells were grown in chamber slides and
treated with either DMSO or 20 nM AZD1152-HQPA
for 48 hours. The chamber slides were rinsed 2× with
cold PBS solution and fixed with 10% formaldehyde
(Sigma). Cells were permeabilized with 0.2% Triton X-
100 (Sigma), stained with DAPI (Invitrogen) and visua-
lized with an Olympus IX81 fluorescent microscope.
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